The findings indicate that GLP-1 RA regulates the expression of Ang II/AT1R/ACE2 and activates the AMPK/mTOR pathway, thereby preventing cardiac hypertrophy [158], suggesting that GLP-1 agonists could be a useful treatment for patients with pathologic cardiac hypertrophy (Figure 3B). Here, AGT is linked to cardiac hypertrophy.